COMMUNIQUÉS West-GlobeNewswire

Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions
30/06/2025
Er-Kim will distribute KIMMTRAK® (tebentafusp) for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, in accordance with applicable local regulations in the agreed regions [...]
IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period
30/06/2025
LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The [...]
Synergy CHC Corp. (NASDAQ: SNYR) Secures Landmark Retail and Distribution Wins Across North America for FOCUSfactor Supplements and Functional Beverages
30/06/2025
Core-Mark National Authorization, Walmart Canada Breakthrough, and Key Regional Wins Highlight Rapid Growth in Functional Beverage and Supplement Categories WESTBROOK, Maine, June 30, 2025 (GLOBE NEWSWIRE) -- Synergy [...]
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
30/06/2025
– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI- [...]
SPR Receives Fourth Consecutive Northeast Ohio Top Workplaces Award
30/06/2025
- Based on employee feedback highlighting strong corporate culture - CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- For the fourth year in a row, SPR has been recognized as a Top Workplace by Northeast Ohio Top Workplaces [...]
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
30/06/2025
Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz ® and RhodoLED ® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG. Under their new [...]
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
30/06/2025
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual [...]
HealthLynked Appoints Andrew Mavliev as Chief Technology and Product Officer to Accelerate Direct-to-Consumer Healthcare Innovation
30/06/2025
NAPLES, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. ( OTCQB: HLYK ), a leader in connected healthcare technology, is pleased to announce the appointment of Andrew Mavliev as its new Chief [...]
Tilde Sciences Announces Availability Of VECAMYL™ (Mecamylamine) With Exclusive Distribution Through Optime Care Specialty Pharmacy
30/06/2025
JERSEY CITY, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tilde Sciences LLC (“Tilde”), a U.S.–based biopharmaceutical company dedicated to developing therapies for rare diseases with significant unmet need, today announced [...]
Tectonic Therapeutic Joins Russell 3000® Index
30/06/2025
WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
30/06/2025
SPRING Trial Data Presented at BSG Live’25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and [...]
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
30/06/2025
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today [...]
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
30/06/2025
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers [...]
Protara Therapeutics Announces Addition to the Russell 3000® Index
30/06/2025
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the [...]
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
30/06/2025
Builds on clearances already received by FDA and EMA China has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc [...]
Spectral AI Announces Submission to FDA of its DeepView® System
30/06/2025
DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and [...]
Catheter Precision, Inc. Forms new Joint Venture Called Kardionav to Exploit patented AI Techniques to Create New VT Software platform
30/06/2025
New AI techniques to add to VT ablation tools FORT MILL, S.C., June 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically [...]
Heartflow to Showcase Landmark DECIDE Data at SCCT 2025, Advancing AI-Driven Care for Coronary Artery Disease
30/06/2025
DECIDE Registry receives top award as company plans to unveil the next generation plaque technology at SCCT Annual Scientific Meeting MOUNTAIN VIEW, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. , the leader [...]
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
30/06/2025
No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1 MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. ( [...]

Pages